The active pharmaceutical ingredient Flurbiprofen was evaluated for its Organoleptic properties and solubility. The results obtained were satisfactory. Flurbiprofen nanoparticles were prepared by emulsion -droplet coalescence method and the polymer concentrations were optimized by various trials In the present study Chitosan nanoparticles containing Flurbiprofen was prepared. The effect of increase in Chitosan concentration on various parameters like particle size and invitro release profile were studied. The Flurbiprofen nanoparticles were formulated and evaluated for its invitro drug release profile. The results showed that the in vitro drug release for FNP1, FNP2, FNP3, FNP4 and FNP5 were found to be 99.45± 0.31, 99.41± 0.17, 99.45± 0.19, 73.65± 0.15 and 69.76± 0.23respectively at the end of 24hr. Based on the drug content,entrapment efficiency,particle size,zeta potential and in vitro drug release profile of Flurbiprofen nanoparticles formulations (FNP1-FNP5) formulation FNP3 was selected as the best formulation in which the particle size was 271.4nm. The in vitro % drug release of FNP3 formulation was 99.45± 0.19 at the end of 24 hr and it was found to be suitable formulation to manage the condition of rheumatoid arthritis. Hence it can be concluded that the newly formulated controlled release nanoparticulate drug delivery systems of Flurbiprofen may be ideal and effective in the management of pain due to arthritis by allowing the drug to release continuously for 24 hr. Key words: Formulation, Optimization, Flurbiprofen, Nanoparticle